Background {#Sec1}
==========

One-fourth of deaths have been attributed to cancers; however, an obvious decline (by 22%) in the rate of cancer-related deaths was observed from 1991 to 2011 \[[@CR1]\]. The number of cancer survivors is growing due to improved treatment outcomes. However, this result may lead to an increasing chance of developing second primary malignant neoplasms (SPMs). It was reported that SPMs accounted for 17 to 19% of new cancer cases \[[@CR2], [@CR3]\]. In addition, the morbidities are increasing year by year, and it is estimated that there may be more than 20 million cancer survivors who are at risk of SPMs by 2026 \[[@CR4]\].

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal disease with an annually increasing incidence. Along with an increased number of cancer survivors who are at a high risk of developing SPMs, PDAC is becoming increasingly frequently developed as a subsequent tumor \[[@CR5], [@CR6]\]. Multiple studies have sought to evaluate the prognostic factors of patients with PDAC as the first primary cancer, while there are few data regarding patients with PDAC as the second primary cancer. Moreover, clinical trials are important for improving the survival of patients, but a history of prior cancer is one of the most commonly used exclusion criteria in clinical trials, which may be a huge treatment hurdle for a large proportion of patients with SPMs \[[@CR7]\]. Given the sizable number of patients with a prior cancer, this exclusion criterion limits the generalizability of inclusion cases in clinical trials. Therefore, it is important to validate this exclusion criterion in clinical trials for patients with PDAC as a second primary cancer.

To address these issues, we aimed to evaluate the prognostic factors and to assess the survival impact of a prior cancer in patients with second primary PDAC using the Surveillance, Epidemiology, and End Results (SEER) database. The findings of this study may provide potential insight into the clinical management and surveillance of patients with PDAC who had a prior cancer.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The data of patients with PDAC from 2004 to 2015 were extracted from the SEER database, using the SEER\*Stat software (v. 8.3.5). The study cohort consisted of patients with the following *International Classification of Diseases for Oncology, Third Edition* (ICD-O-3) histology codes 8140/3, 8144/3, 8255/3, 8261/3, and 8263/3, as well as the ICD-O-3 site codes C25.0, C25.1, C25.2, C25.3, C25.7, C25.8, and C25.9. For patients with prior cancers, ICD-O-3 was used to identify the types of primary solid tumors. Patients who were younger than 18 years, who did not have pathologically confirmed PDAC or who had missing information about clinical factors were excluded from this study.

Data collection {#Sec4}
---------------

Records for age at diagnosis, gender, tumor size, tumor grade, tumor site, tumor-node-metastasis (TNM) stage, treatment, follow-up information, and causes of death were obtained using the SEER registries. The sequence numbers of all primary tumors of patients with PDAC were determined to ascertain whether they had a prior cancer. The time interval between the prior cancer and the index cancer was calculated, and a latency period of at least 6 months was adopted to avoid the possibility of synchronous metastases. The dataset from the SEER database that was generated and analyzed during the current study is available in the SEER dataset repository (<https://seer.cancer.gov/>).

Statistical analysis {#Sec5}
--------------------

Survival time was defined as the time period from diagnosis to the last follow-up or deaths due to all causes (overall survival, OS) or cancer-specific mortalities (cancer-specific survival, CSS). Pearson's chi-squared tests were used to assess the associations between clinicopathological characteristics and patient groups. A one-to-ten nearest propensity score matching (PSM) analysis with a caliper of 0.2 was performed by a logistic regression model, using the following characteristics as covariates: age, tumor site and grade, T and N stage, surgery, radiotherapy, and chemotherapy. The score-matched cohorts were used in the subsequent analyses. The cancer-specific mortality, non-cancer-specific mortality, and OS of patients with certain types of cancers were compared with those factors of patients without prior cancers. Cancer-specific and non-cancer-specific mortality were regarded as two competing events. Fine and Grey's model was used to estimate the subhazard ratios of variables in the analyses of overall mortalities and cancer-specific mortalities \[[@CR8], [@CR9]\]. The Kaplan-Meier method was used to determine OS, and survival differences between groups were compared by the log-rank test. The hazard ratio (HR) and the associated 95% confidence interval (CI) were also calculated.

Statistical analyses were performed using R software (v 3.4.2, The R Foundation for Statistical Computing, Vienna, Austria, <http://www.r-project.org>). A two-tailed *P*-value \< 0.05 was considered statistically significant.

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

We initially identified 9235 patients with PDAC from the SEER database, including 438 (4.74%) patients with a prior cancer and 8797 (95.26%) patients without a prior cancer, and their baseline clinicopathological characteristics were compared (Table [1](#Tab1){ref-type="table"}). In contrast to patients with prior cancer, those without cancer were younger, had a larger proportion of pancreatic head cancer, had a larger tumor, were in advanced TNM stages and were more likely to receive surgery and chemotherapy. To equilibrate these significantly different baseline characteristics, a PSM analysis was adopted. A total of 438 patients with prior cancers and 4380 patients without were matched, and the variables were balanced between these two groups. Among the 438 patients with a prior cancer, prostate cancer (28.8%) was the most common initial tumor, followed by breast (25.1%), renal and bladder (11.6%), colon and rectum (9.8%), uterine (5.5%), lung (3.7%), small intestinal (3.4%), oral (3.0%), stomach (2.7%), and hepatocellular (1.8%) cancer.Table 1Comparisons of clinicopathological characteristics of patientsCharacteristicBefore PSMAfter PSMEffect sizeWithout prior cancerWith prior cancerTotal number*P* valueWithout prior cancerWith prior cancerTotal number*P* valueTotal number8797438923543804384818Age (years)≤ 602683432726\< 0.001429434721.0000.001\>  606114395650939513954346GenderFemale420121344140.732213821323510.9600.002Male4596225482122422252467RaceBlack11134811610.186519485670.4870.020White6937361729835123613873Others7472977634929378Tumor siteHead521423354470.018249823327310.0510.241Body113580121557480654Tail114360120361360673Pancreatic duct6623369532833361Others6433267536732399Tumor size (cm)≤ 2858539110.261442534950.4160.0192\~44429218464722402182458\> 43510167367716981671865Tumor gradeWell915449590.019492445360.432−0.020Moderate3708191389918841912075Poor4024187421118961872083Undifferentiated1501616610816124T stageT0332350.006252270.1730.159TI3322535719025215TII1848118196610131181131TIII4799214501323742142588TIV178579186477879857N stageN0446425447180.012246225427160.735−0.006N13398146354415021461648N29353897341638454MetastasisAbsent472824349710.492240224326450.8010.006Present4069195426419781952173TNM stageI551485590.001358484060.2370.172II2623131275413451311476III155464161869964763IV4069195426419781952173SurgeryPerformed34081613569\< 0.001161016117710.1030.189Recommended, not performed2452827318528213Not recommended5144249539325852492834RadiotherapyNo760539379980.052384039342330.220−0.172Yes119245123754045585ChemotherapyNo316018033400.029175218019320.6830.005Yes5637258589526282582886*LN* Lymph node metastasis, *TNM* Tumor-node-metastasis stage

Comparison of OS rates in patients with and without a prior cancer {#Sec8}
------------------------------------------------------------------

In the whole study cohort, the median OS rates during the follow-up period were 7 and 8 months for patients with and without prior cancer, respectively. In addition, patients with and without a prior cancer had comparable survival rates after the PSM analysis. The 1-, 2-, and 3-year OS rates were 35.3, 18.3, 10.9 and 35.1%, 18.1, 11.7% for patients with and without a prior cancer, respectively (Table [2](#Tab2){ref-type="table"}). When stratified by initial cancer sites, compared with patients without prior cancer, the survivors of prostate, lung, small intestinal, oral, stomach, and hepatocellular cancers had a slightly better short-term survival, and the survivors of other types of prior cancers had a slightly better long-term survival; however, these survival differences were not significant (Fig. [1](#Fig1){ref-type="fig"}). In addition, similar results were shown in the subgroup analyses of OS stratified by time interval among the whole cohort (Additional file [1](#MOESM1){ref-type="media"}: Table S1).Table 2Cumulative incidences of mortality of patientsCancer typeNoCancer-specific mortality (%)*p* ^a^Non-cancer-specific mortality (%)*p* ^a^1-year (95% CI)2-year (95% CI)3-year (95% CI)1-year (95% CI)2-year (95% CI)3-year (95% CI)Whole cohort923560.6(60.5--60.7)77.8(77.9--77.8)84.4(84.3--84.5)2.7(2.6--2.8)3.5(3.4--3.6)3.8(3.7--3.9)Without prior cancer879760.9(60.8--70.0)78.2(78.1--78.3)84.9(84.8--85.0)2.3(2.2--2.4)3.0(2.9--3.1)3.3(3.2--3.4)Prostate cancer12659.5(59.1--59.9)69.6(69.3--70.0)80.8(80.5--81.1)0.2379.1(9.0--9.2)12.1(11.9--12.3)12.1(11.9--12.3)\< 0.001Breast cancer11062.4(61.9--62.9)78.6(78.1--79.1)84.7(84.2--85.2)0.0295.8(5.6--6.0)8.3(8.1--8.5)8.3(8.1--8.5)\< 0.001Renal and bladder cancer5152.2(51.1--53.3)64.1(63.1--65.1)72.1(71.0--73.1)0.06712.2(11.2--13.2)14.6(13.6--15.6)14.6(13.6--15.6)\< 0.001Colon and rectal cancer4360.5(59.3--61.6)75.4(74.5--76.3)78.4(77.5--79.3)0.7469.3(8.9--9.7)9.3(8.9--9.7)9.3(8.9--9.7)0.033Uterine cancer2449.4(47.0--51.8)54.6(52.2--57.1)54.6(52.2--57.1)0.0638.8(8.1--9.6)8.8(8.1--9.6)8.8(8.1--9.6)0.096Lung cancer1638.8(36.1--41.5)73.1(68.9--77.3)73.1(68.9--77.3)0.01713.1(10.6--15.6)13.1(10.6--15.6)13.1(9.1--17.1)\< 0.001Small intestinal cancer1542.0(38.2--45.8)53.7(36.6--67.4)NA0.07614.0(12.1--15.9)34.5(28.7--40.4)NA\< 0.001Oral cancer1340.4(36.1--44.7)75.0(71.1--78.9)NA0.4567.7(6.5--8.9)7.7(6.5--8.9)NA0.008Gastric cancer1253.8(48.0--59.6)90.3(76.7-)NA0.9859.7(7.7--11.7)9.7(7.7--11.7)NA0.204Hepatocellular cancer850.0(42.3--57.7)62.5(54.2--70.8)62.5(54.2--70.8)0.21712.5(9.4--15.6)25.0(18.9--31.1)25.0(18.9--31.1)\< 0.001Matched cohort481861.8(61.7--61.9)77.7(77.6--77.8)83.8(83.7--83.9)3.1(3.0--3.2)4.1(4.0--4.2)4.5(4.4--4.6)Without prior cancer438062.4(62.3--62.5)78.6(78.6--84.7)84.7(84.5--84.8)2.4(2.3--2.5)3.2(3.1--3.3)3.6(3.5--3.7)Prostate cancer12659.5(59.1--59.9)69.6(69.3--70.0)80.8(80.5--81.1)0.1739.1(9.0--9.2)12.1(11.9--12.3)12.1(11.9--12.3)\< 0.001Breast cancer11062.4(61.9--62.9)78.6(78.1--79.1)84.7(84.2--85.2)0.0745.8(5.6--6.0)8.3(8.1--8.5)8.3(8.1--8.5)0.001Renal and bladder cancer5152.2(51.1--53.3)64.1(63.1--65.1)72.1(71.0--73.1)0.05112.2(11.2--13.2)14.6(13.6--15.6)14.6(13.6--15.6)\< 0.001Colon and rectal cancer4360.5(59.3--61.6)75.4(74.5--6.3)78.4(77.5--79.3)0.6549.3(8.9--9.7)9.3(8.9--9.7)9.3(8.9--9.7)0.058Uterine cancer2449.4(47.0--51.8)54.6(52.2--57.1)54.6(52.2--57.1)0.0518.8(8.1--9.6)8.8(8.1--9.6)8.8(8.1--9.6)0.123Lung cancer1638.8(36.1--41.5)73.1(68.9--77.3)73.1(68.9--77.3)0.21513.1(10.6--15.6)13.1(10.6--15.6)13.1(9.1--17.1)0.052Small intestinal cancer1542.0(38.2--45.8)53.7(36.6--47.4)NA0.06514.0(12.1--15.9)34.5(28.7--40.4)NA\< 0.001Oral cancer1340.4(36.1--44.7)75.0(71.1--78.9)NA0.4127.7(6.5--8.9)7.7(6.5--8.9)NA0.013Gastric cancer1253.8(48.0--59.6)90.3(76.7-)NA0.9229.7(7.7--11.7)9.7(7.7--11.7)NA0.238Hepatocellular cancer850.0(42.3--57.7)62.5(54.2--70.8)62.5(54.2--70.8)0.20712.5(9.4--15.6)25.0(18.9--31.1)25.0(18.9--31.1)0.001*NA* Not available, *CI* Confidence interval*p*^a^-values represented the differences of cancer-specific mortalities or non-cancer-specific mortalities between patients with certain kind of prior tumor and those without prior tumorFig. 1Overall survival analysis in patients with PDAC who had a prior cancer: **a** cohort before the PSM analysis; **b** cohort after the PSM analysis; **c** prostate cancer; **d** breast cancer; **e** renal and bladder cancer; **f** colon and rectal cancer; **g** uterine cancer; **h** lung cancer; **i** small intestinal cancer; **j** oral cancer; **k** gastric cancer; **l** hepatocellular cancer. PDAC: pancreatic ductal adenocarcinomas; PSM: propensity score matching

Comparison of mortalities in patients with and without a prior cancer {#Sec9}
---------------------------------------------------------------------

During the follow-up period, there were 296 (84.8%) cancer-specific and 53 (15.2%) non-cancer-specific mortalities in patients with a prior cancer. In patients without a prior cancer, 6578 (96.0%) cancer-specific and 272 (4.0%) non-cancer-specific mortalities were observed before the PSM analysis, and the 1-, 2-, and 3-year overall, cancer-specific, and non-cancer-specific mortalities were 63.3, 81.2, and 88.3%; 60.6, 77.8, and 84.4%; 2.7, 3.5, and 3.8%, respectively. After the PSM analysis, 3315 (95.7%) cancer-specific and 150 (4.3%) non-cancer-specific mortalities were observed. The 1-, 2-, and 3-year overall, cancer-specific and non-cancer-specific mortalities are provided in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. When stratified by initial cancer sites, the patients with a prior cancer had comparatively lower cancer-specific mortalities, although no significant differences were found. In addition, compared with patients without prior cancer, patients with a history of prostate, breast, renal and bladder, small intestinal, oral, or hepatocellular cancer had significantly more competing mortalities (Fig. [2](#Fig2){ref-type="fig"}).Table 3Overall survival rates of patientsCancer typeNoOverall survival rates (%)HR (95% CI)*p* ^a^1-year (95% CI)2-year (95% CI)3-year (95% CI)Whole cohort923536.7(36.6--36.7)18.7(18.6--18.7)11.7(11.6--11.7)Without prior cancer879736.8(36.7--36.9)18.7(18.6--18.8)11.7(11.6--11.8)Prostate cancer12635.6(35.3--35.8)21.4(21.1--21.5)13.3(13.1--13.5)1.137(0.928--1.393)0.171Breast cancer11036.5(36.4--36.6)16.6(16.5--16.7)14.7 (14.6--14.8)0.966(0.780--1.197)0.749Renal and bladder cancer5135.6(35.5--35.7)21.4(21.3--21.5)13.3(13.2--13.4)1.004(0.732--1.376)0.980Colon and rectal cancer4330.2(30.1--30.3)15.3(15.2--15.4)12.3(12.2--12.4)1.149(0.813--1.624)0.382Uterine cancer2441.8(41.6--42.0)36.6(36.4--36.8)36.6(36.4--36.8)0.700(0.451--1.086)0.165Lung cancer1649.2(49.0--49.4)16.4(16.2--16.6)8.2(8.1--8.4)0.865(0.531--1.408)0.572Small intestinal cancer1544.0(43.7--44.3)11.7(11.5--11.9)11.7(11.5--11.9)0.948(0.533--1.687)0.855Oral cancer1351.9(51.6--52.2)17.3(17.1--17.5)0.00.976(0.544--1.752)0.935Gastric cancer1236.5(36.2--36.8)0.00.01.150(0.571--2.318)0.663Hepatocellular cancer837.5(37.2--37.8)12.5(12.3--12.7)12.5(12.3--12.7)1.014(0.481--2.138)0.971Matched cohort481835.1(35.0--35.2)18.2(18.1--18.2)11.7(11.7--11.7)Without prior cancer438033.0(32.9--33.1)18.2(18.1--18.3)11.7(11.6--11.7)Prostate cancer12635.6(35.3--35.5)21.4(21.1--21.5)13.3(13.1--13.5)0.967(0.708--1.318)0.826Breast cancer11036.5(36.4--36.6)16.6(16.5--16.7)14. (14.6--14.8)0.927(0.751--1.145)0.481Renal and bladder cancer5135.6(35.5--35.7)21.4(21.3--21.5)13.3(13.2--13.4)0.967(0.709--1.318)0.826Colon and rectal cancer4330.2(30.1--30.3)15.3(15.2--15.4)12.3(12.2--12.4)1.107(0.788--1.557)0.521Uterine cancer2441.8(41.6--42.0)36.6(36.4--36.8)36.6(36.4--36.8)0.676(0.439--1.041)0.125Lung cancer1649.2(49.0--49.4)16.4(16.2--16.6)8.2(8.048--8.352)0.842(0.520--1.364)0.504Small intestinal cancer1544.0(43.7--44.3)11.7(11.5--11.9)11.7(11.5--11.9)0.908(0.517--1.596)0.739Oral cancer1351.9(51.6--52.2)17.3(17.1--17.5)0.00.943(0.531--1.676)0.840Gastric cancer1236.5(36.2--36.8)0.000.01.093(0.552--2.167)0.781Hepatocellular cancer837.5(37.2--37.8)12.5(12.3--12.7)12.5(12.3--12.7)0.982(0.471--2.010)0.961*CI* Confidence interval*p*^a^-values represented the differences of overall survival rates between patients with certain kind of prior tumor and those without prior tumorFig. 2All-cause, cancer-specific, and competing mortality analysis in patients with PDAC who had a prior cancer: **a** cohort before the PSM analysis; **b** cohort after the PSM analysis; **c** prostate cancer; **d** breast cancer; **e** renal and bladder cancer; **f** colon and rectal cancer; **g** uterine cancer; **h** lung cancer; **i** small intestinal cancer; **j** oral cancer; **k** gastric cancer; **l** hepatocellular cancer. PDAC: pancreatic ductal adenocarcinomas; PSM: propensity score matching

Comparison of the OS rates separated by the time interval {#Sec10}
---------------------------------------------------------

The overall median time interval from initial cancer to second primary cancer was 103.5 months. The time interval exceeded 60 months in patients with a history of prostate (97.0 months), breast (129.5 months), renal and bladder (68.0 months), colon and rectum (69.0 months), uterine (193.5 months), lung (65.5 months), small intestinal (94.0 months) or oral (127.0 months) cancer. It was shown in this study that there were some overlaps in the survival curves for patients with and without prior cancer, which indicated that the proportional hazards assumption was not satisfied. Similar to many clinical trials in which the 5-year time interval was used as an exclusion window \[[@CR10]\], in this study, we adopted the 5-year period as a cutoff value for the time interval from initial cancer to second primary cancer. There were 147 (33.6%) PDACs that occurred within this time interval in patients with a prior cancer. There were no significant differences in OS for patients with and those without a prior cancer regardless of whether the PDAC occurred within or beyond the 5-year time interval (Table [4](#Tab4){ref-type="table"}), with an exception for patients with a history of breast cancer. When PDAC occurred within the 5-year time interval, the patients with prior breast cancer had a significantly better survival compared with those without a prior cancer (*p* \< 0.001). However, inferior survival was observed in patients who developed secondary PDAC occurring beyond the 5-year time interval (*p* \< 0.001).Table 4Subgroup analysis of prior cancer history impact on overall survival stratified by the time interval in matched cohortTime interval ≤ 5 yearsTime interval \> 5 yearsNo1-year OS rates ((95% CI))2-year OS rates (95% CI)3-year OS rates (95% CI)HR*p* ^b^No1-year OS rates (95% CI)2-year OS rates (95% CI)3-year OS rates (95% CI)HR*p* ^b^Without prior cancer438033.0(32.9--33.2)18.2(18.1--18.4)11.7(11.6--11.8)438033.0(32.9--33.2)18.2(18.1--18.4)11.7(11.6--11.8)Prostate cancer4442.9(42.8--43.0)28.6(28. 5--28.7)9.5(9.4--9.6)0.905(0.670--1.220)0.5208224.4(24.3--24.5)11.3(11.2--11.4)5.6(5.5--5.7)1.249(0.956--1.632)0.058Breast cancer25100.053.9(53.7--54.1)47.9(47.7--48.1)0.309(0.228--0.420)\< 0.0018512.8(12.7--12.9)2.7(2.7--2.7)2.7(2.7--2.7)1.489(1.115--1.987)\< 0.001Renal and bladder cancer2333.1(32.9--33.3)26.5(26.3--26.7)0.01.073(0.645--1.785)0.7692837.8(37.6--38.0)18.9(18.8--19.0)14.2(14.1--14.3)0.904(0.612--1.340)0.617Colon and rectal cancer2040.0(39.8--40.2)12.0(11.8--12.2)12.0(11.8--12. 2)0.941(0.593--1.494)0.7952321.7(21.5--21. 9)17.4(17.2--17.6)11.6(11.5--11.7)1.300(0.789--2.150)0.219Uterine cancer366.7(66.2--67.2)66.7(66.2--67.2)66.7(66.2--67.2)0.377(0.113--1.257)0.2912137.8(37.6--38.0)32.4(32.2--32.6)NA0.719(0.453--1.143)0.216Lung cancer862.5(62.2--62.8)15.6(15.3--15.9)0.00.751(0.395--1.429)0.430837.5(37.2--37.8)18.8(18.5--19.1)18.8(18.5--19.1)0.958(0.464--1.980)0.906Small intestinal cancer625.0(24.6--25.4)25.0(24.6--25.4)25.0(24.6--25.4)1.180(0.406--3.400)0.737955.6(55.3--55.9)0.00.00.804(0.413--1.560)0.547Oral cancer3100.033.3(32.8--33.8)33.3(32.8--33.8)0.441(0.175--1.106)0.2161047.6(47.3--47.9)19.0(18.8--19.2)0.00.964(0.524--1.773)0.904Gastric cancer721.4(21.1--21.7)0.00.01.274(0.516--3.145)0.535560.0(59.8--60.4)30.0(29.5--30.5)30.0(29.5--30.5)0.852(0.299--2.421)0.772Hepatocellular cancer633.3(32.9--33.7)16.7(16.4--17.0)16.7(16.4--17.0)0.942(0.402--2.206)0.889250.0(49.3--50.7)0.00.01.101(0.257--4.720)0.887*CI* Confidence interval, *HR* Hazard ratio, *NA* Not available, *OS* Overall survival*p*^b^-values represented the differences of overall survival rates between patients with certain kind of prior tumor and those without prior tumor

Univariate and multivariate analyses of OS {#Sec11}
------------------------------------------

The clinical and pathological variables were included in the univariate and multivariate analyses to identify the prognostic factors of OS. A history of prior cancer was not associated with OS in the study cohort before or after the PSM analysis. Variables such as tumor size and grade, N stage, metastasis, surgery, radiotherapy, and chemotherapy were identified as prognostic factors of OS for all patients, for those without a prior cancer, and for those with a prior cancer (Table [5](#Tab5){ref-type="table"}, Additional file [2](#MOESM2){ref-type="media"}: Table S2 and Additional file [3](#MOESM3){ref-type="media"}: Table S3, respectively). Among patients with a prior cancer, there was no increase in the risk of decreased survival compared with those without a prior cancer.Table 5Univariate and multivariate analyses of OSCharacteristicBefore PSMAfter PSMUnivariate analysisMultivariate analysisUnivariate analysisMultivariate analysisHR95%CI*p*HR95%CI*p*HR95% CI*p*HR95% CI*p*Age (years)≤ 60ReferenceReferenceReferenceReference\>  601.1861.128--1.248\< 0.0011.2031.143--1.267\< 0.0011.2281.101--1.371\< 0.0011.1501.030--1.2840.013GenderFemaleReferenceNIReferenceNIMale1.0460.999--1.0960.0531.0110.948--1.0770.746RaceBlackReferenceReferenceReferenceReferenceWhite0.9050.845--0.9700.0050.9340.872--1.0020.0560.8980.814--0.9910.0320.9310.843--1.0280.156Others0.8900.804--0.9860.0260.9200.830--1.0200.1130.8750.755--1.0130.0740.9480.818--1.0990.477Tumor siteHeadReferenceReferenceReferenceReferenceBody1.3631.273--1.461\< 0.0010.9290.865--0.9980.0431.3071.188--1.437\< 0.0010.9660.874--1.0660.489Tail1.4121.317--1.513\< 0.0010.9880.919--1.0620.7511.4561.326--1.599\< 0.0011.0390.942--1.1460.443Pancreatic duct1.4581.336--1.590\< 0.0010.9950.910--1.0890.9211.4831.314--1.674\< 0.0011.0190.899--1.1560.769Others1.4241.304--1.555\< 0.0010.9710.886--1.0640.5221.4591.299--1.638\< 0.0010.9310.824--1.0530.254Tumor size (cm)≤ 2ReferenceReferenceReferenceReference2\~41.4291.310--1.559\< 0.0011.1591.034--1.3000.0111.3921.238--1.564\< 0.0011.2151.033--1.4300.019\> 42.1621.980--2.361\< 0.0011.4071.252--1.581\< 0.0012.1271.888--2.397\< 0.0011.4591.236--1.722\< 0.001Tumor gradeWellReferenceReferenceReferenceReferenceModerate1.1161.028--1.2120.0091.2331.135--1.339\< 0.0011.0300.923--1.1480.5991.2041.078--1.3450.001Poor1.6011.476--1.736\< 0.0011.5841.459--1.719\< 0.0011.4121.267--1.573\< 0.0011.4461.295--1.615\< 0.001Undifferentiated1.6971.416--2.034\< 0.0011.3571.131--1.6280.0011.6331.320--2.019\< 0.0011.3771.111--1.7070.004T stageT0ReferenceReferenceReferenceReferenceT10.2000.139--0.287\< 0.0010.3340.231--0.483\< 0.0010.2500.164--0.380\< 0.0010.3740.242--0.577\< 0.001T20.4710.335--0.661\< 0.0010.4510.313--0.650\< 0.0010.5470.370--0.8070.0020.4800.311--0.7420.001T30.2880.205--0.404\< 0.0010.4440.309--0.638\< 0.0010.3510.238--0.517\< 0.0010.4830.313--0.7430.001T40.4800.342--0.674\< 0.0010.4500.313--0.648\< 0.0010.5780.391--0.8550.0060.4620.299--0.714\< 0.001N stageN0ReferenceReferenceReferenceReferenceN10.9250.881--0.9710.0021.1001.046--1.156\< 0.0010.9050.845--0.9690.0041.0961.021--1.1760.011N20.5910.544--0.641\< 0.0011.3961.268--1.537\< 0.0010.5750.511--0.647\< 0.0011.4081.226--1.616\< 0.001MetastasisAbsentReferenceReferenceReferenceReferencePresent2.8742.739--3.015\< 0.0011.7021.608--1.802\< 0.0012.9112.723--3.112\< 0.0011.7191.589--1.859\< 0.001SurgeryPerformedReferenceReferenceReferenceReferenceRecommended, not performed3.3672.948--3.846\< 0.0012.5702.232--2.959\< 0.0013.3652.881--3.929\< 0.0012.6262.221--3.105\< 0.001Not recommended3.4313.255--3.618\< 0.0012.6082.419--2.813\< 0.0013.5823.323--3.861\< 0.0012.6842.416--2.982\< 0.001RadiotherapyNoReferenceReferenceReferenceReferenceYes0.3690.341--0.399\< 0.0010.8870.813--0.9690.0080.3690.330--0.412\< 0.0010.8600.759--0.9740.017ChemotherapyNoReferenceReferenceReferenceReferenceYes0.4450.425--0.467\< 0.0010.4350.414--0.457\< 0.0010.4500.422--0.480\< 0.0010.4510.422--0.483\< 0.001Prior cancerWithoutReferenceReferenceReferenceReferenceWith1.0300.925--1.1470.5871.0140.910--1.1300.7960.9930.889--1.1080.8941.0180.912--1.1360.754*OS* Overall survival, *HR* Hazard ratio

Discussion {#Sec12}
==========

Over the last few decades, the dramatic improvement in the prognosis of many types of cancers has led to the increased development of a second primary cancer. Similar to other types of cancers \[[@CR7], [@CR10], [@CR11]\], PDAC is more and more frequently emerging as a second primary cancer. In this study, 4.74% of the patients with PDAC were accompanied with a prior cancer. Prostate, breast, and renal and bladder cancers were the three most commonly observed types of prior cancers in patients with PDAC. A genetic predisposition, such as the mutation of *BRCA2* \[[@CR12], [@CR13]\], and some environmental risk factors, such as alcohol, tobacco, and a lack of physical exercises \[[@CR14]\], contributed to the excess risks of multiple cancers in patients with PDAC. In this study, the median time intervals from initial cancer to second primary PDAC were different for different types of cancers. The variations in time intervals suggest that it is necessary to screen for PDAC in cancer survivors and provide clues to guide screening strategies or screening intervals for patients with PDAC as a second primary cancer.

There is a widely accepted rule in clinical trials according to which patients with prior cancers are to be excluded. The assumption of prior cancers impacting survival outcomes contributes to this exclusion rule, which further limits the authenticity and generalizability of results of the clinical trials with this exclusion criterion \[[@CR7]\]. Moreover, this assumption has not been proven on the basis of authoritative data, especially for patients with PDAC as a second primary cancer. In this study, compared with mortalities from prior cancers, more cancer-related mortalities were observed in patients with PDAC as a second primary tumor. In addition, patients with PDAC who had a prior cancer had a median survival of 7 months, which is comparable to that of patients with PDAC who did not have a prior cancer. Even after balancing the baseline characteristics using the PSM analysis, patients with PDAC with a prior cancer andthose without a prior cancer had almost overlapping survival curves and cumulative mortality curves, indicating that there was no negative impact on survival outcomes from prior cancers in patients with PDAC. Similar results were supported by studies in patients with lung cancer \[[@CR10], [@CR11]\]. Moreover, when stratified by initial tumor sites, a possible long-term survival benefit and decreased cancer-specific mortalities were observed, especially in survivors of breast, colon and rectum, renal and bladder and uterine cancers, although the survival differences were not significant. These results indicated that certain types of prior cancers may result in improved rather than inferior survival outcomes in patients with PDAC. Interestingly, non-cancer-specific mortalities were higher in patients with certain types of prior cancers. It is possible that a smaller proportion of older patients contributed to this discrepancy.

Considering the importance of details regarding time intervals from initial cancer to second primary cancer, we adopted the 5-year time interval, which is often used as an exclusion window in clinical trials \[[@CR10]\], as the cutoff value for the time interval in this study. When stratified by the time interval, different impacts of a prior cancer on survival were observed in patients with PDAC who initially had breast cancer. Compared to patients with PDAC who did not have a prior cancer, those with a prior cancer had better survival when PDAC developed within 5 years from the initial cancer, whereas a prior history indicated a negative effect on the survival of patients in whom PDAC developed later than within 5 years from the initial cancer. This discrepancy showed that the time interval was probably an important factor that should be considered when evaluating the prognostic impact of a history of cancer, especially in patients with breast tumors as the initial cancer. Except for breast cancer, a consistent survival effect and significance among the whole study cohort were observed for other types of prior cancers. For most types of prior cancers, survivors with PDAC had similar survival rates, regardless of the time interval within or beyond 5 years from their initial cancer diagnosis. This consistent effect and its significance were consistent with the results of previous cohort studies \[[@CR7]\].

Time-dependent survival analyses further illustrated that a prior cancer had little impact on the survival of patients with PDAC. Consistent with our results, Zhou et al. also found that prior cancer did not have an adverse impact on the all-cause survival of patients with PDAC \[[@CR7]\]. In addition, the independent prognostic factors for PDAC as the second primary cancer were similar to those for PDAC as the first primary tumor \[[@CR15]--[@CR18]\]. A history of prior cancer was not associated with OS for patients with PDAC. Potential explanations may include biological effects and regular follow-up examinations. First, PDAC that developed as a second primary cancer accounted for a small proportion of all cases of PDAC. The biologically independent nature and extremely high degree of malignancy made it responsible for most of the cancer-specific mortalities \[[@CR6]\]. Second, regular routine follow-up after the diagnosis of an initial cancer contributed to the early diagnosis of subsequent PDAC. Additionally, the reduced exposure to risk factors such as alcohol and tobacco demonstrated a favorable prognosis for patients with PDAC. The differences between the matched population and true population might have led to some biases in the survival analyses, which was the weakness of this study. However, comparisons of the survival analyses showed that there were only small differences in survival between the matched and whole cohorts, which represented the true PDAC population. In addition, the risk factors identified in patients with and without prior cancer were almost the same. The comparisons of results on the basis of different cohorts can further illustrate that there was only a small impact of prior cancer in the survival analyses of patients with PDAC.

In the current study, there was only a small impact of prior cancer on OS and cancer-specific mortalities in patients with PDAC on the basis of a large study cohort. This finding inspired us to reevaluate the long-accepted assumption that a history of prior cancer was incorporated into the exclusion criteria in clinical trials. It is the first time that the survival impact of a prior cancer in patients with PDAC was investigated, and our study provides the data to address this issue as an exclusion criterion in clinical trials. The expanded inclusion criteria of patients with PDAC who had prior cancers would probably increase the accuracy and generalizability of the results from clinical trials.

There were several limitations to this study. First, the retrospective nature made it challenging to balance all the clinicopathological characteristics, even after the PSM analysis. Second, the information about prior cancers was limited. Apart from the sequence number and time interval of multiple cancers, some detailed clinicopathological features about the prior cancers were unavailable in the SEER dataset. In addition, the SEER dataset lacked detailed information on treatments, such as surgery, radiotherapy, and chemotherapy, and lifestyle factors, such as body mass index and smoking status. Third, although the total number of patients with PDAC who had prior cancers was relatively large, cases of a certain type of cancer represented a small proportion of patients. In addition, the matched cohort selected by the PSM analysis did not represent the true PDAC population; therefore, there might be some biases in the survival analyses, which should be addressed. A larger cohort study is needed to confirm the results of this study.

Conclusions {#Sec13}
===========

In conclusion, our study evaluated the prognostic impact of prior cancer in patients with PDAC. The history of a prior cancer caused no significant differences in the overall survival or cancer-specific mortality rates. The inclusion of patients with a prior cancer in the clinical trials of PDAC should be considered. However, further studies are needed to confirm these results.

Additional files
================

 {#Sec14}

Additional file 1:**Table S1.** Subgroup analysis of the impact of a prior cancer on overall survival stratified by the time interval from the prior diagnosis among the whole cohort. This table shows the survival differences between patients without prior cancer and those with different kinds of cancers. (DOCX 19 kb) Additional file 2:**Table S2.** Univariate and multivariate analyses of overall survival in patients without prior cancer. This table shows the significant predictors of overall survival in patients without prior cancer. (DOCX 23 kb) Additional file 3:**Table S3.** Univariate and multivariate analyses of overall survival in patients with a prior cancer. This table shows the significant predictors of overall survival in patients with a prior cancer. (DOCX 20 kb)
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:   Confidence interval
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:   Cancer-specific survival

HR

:   Hazard ratio
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:   Overall survival

PDAC

:   Pancreatic ductal adenocarcinoma

PSM

:   Propensity score matching

SEER

:   Surveillance, Epidemiology, and End Results

SPM

:   Second primary malignant neoplasms

TNM

:   Tumor-node-metastasis
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